•$Silvergate Capital (SI.US)$+10.7% (Silvergate (ticker: SI) notched net income of $38.6 million in the June quarter, delivering earnings per share (EPS) of $1.13.)
•$AxoGen (AXGN.US)$+3.3% (guides Q2 revs above consensus; also makes changes to its commercial organization),
•$Novartis AG (NVS.US)$+ 3% (The Swiss pharmaceutical company on Tuesday posted net profit of $1.69 billion, down from $2.89 billion a year earlier.)
•$Halliburton (HAL.US)$+1.1% (the oil services company beat profit and revenue expectations, as pricing gains across all product lines supported margin expansion.)
•$Hasbro (HAS.US)$+0.5% (The Pawtucket, R.I.-based toy and entertainment company reported a net profit of $142 million, or $1.02 a share, compared with a loss of $22.9 million, or 17 cents a share, in the year-ago quarter.)
•$Mandiant (MNDT.US)$+2.1% (DOJ grants early termination of the waiting period re merger with Google)
•$AstraZeneca (AZN.US)$+1.7% (Enhertu approvedinthe EU for patients with HER2-positive metastatic breast cancer treated with one or more prior anti-HER2-based regimens)
•$Incyte (INCY.US)$+1.4% (FDA Approval of Opzelura cream for the treatment of vitiligo)
•$Netflix (NFLX.US)$+1.3% (asking customers in five Latin America countriestopay a fee to use shared passwords according to Bloomberg)
•$Boeing (BA.US)$+1% (777 partners expands 737 MAX fleet ordering up to66more fuel-efficient jets)
Losers:
In reaction to earnings/guidance:
•$Invitae (NVTA.US)$-12% (provides guidance, realigns operations, names new CEO),
•$Signature Bank (SBNY.US)$-8.3% (Signature Bank reported Q2 earnings Tuesday of $5.26 per diluted share, up from $3.57 a year earlier.)
•$IBM Corp (IBM.US)$-6.3% (the company reported better-than-expected results, but said its full-year free cash flow would be lower than thought and concerns over guidance weighed doubt on investors' minds.)
•$Lockheed Martin (LMT.US)$-4.5% (the aerospace and defense contractor reported second-quarter results that missed analysts' profit and sales estimates)
•$Ally Financial (ALLY.US)$-4.4% (the financial-services company posted net income of $454 million, down from $900 million a year earlier. Earnings were $1.40 a share, compared with $2.41 a share.
)
Other news:
•$Clene (CLNN.US)$-5.2% (receives positive EMA opinion on Orphan Drug Designation for CNM-Au8)